Indian Gout Disease Treatment Market size stood at USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Gout is a systemic disease that results from the deposition of monosodium urate crystals (MSU) in tissues. Symptoms of gout include intense pain, swelling, and stiffness in the joints. Gout now affects 0.3% of the Indian population. Prevalence rises up to 10% in men and 6% in women more than 80years old. Annual incidence of gout is 2.68 per 1000 persons. It occurs in men 26 folds more than women. The factors such as government initiatives and support, rising demand for advanced treatment, and growing market players offering newer products are likely to drive the market. Rising prevalence of gout across the nation due to changing lifestyle is likely to boost the industry over the coming years. Increasing alcohol consumption, high purine diet, rising obesity & kidney diseases amongst people, and consumption of certain medications such as diuretics are likely to further boost the incidence of gout.



Market Drivers

The gout therapeutics market is primarily driven by increasing prevalence of this condition, due to changing lifestyle pattern and growing geriatric population. Furthermore, growing research and development activities focusing on innovation and development of gout therapeutic agents and growing awareness associated with the treatment of gout are further stimulating the industry growth. Additionally, growing innovations in the field of biologics and increasing adoption of these products based on their ability to produce powerful anti-inflammatory action. There are large number of clinical trials in process, due to which many new products are expected to be launched in coming few years. This is also expected to propel the industry growth during the forecast period.